[A Case of HER2-Positive Recurrent Breast Cancer and Liver Metastases of GIST Treated with Combined Anti-HER2 Therapy and Imatinib].
Gan To Kagaku Ryoho
; 48(13): 1725-1727, 2021 Dec.
Article
en Ja
| MEDLINE
| ID: mdl-35046310
ABSTRACT
A 70-year-old female with liver metastases from gastrointestinal stromal tumor(GIST)that were found 3 months after partial gastrectomy for the primary GIST underwent Auchincloss operation for left breast cancer with ipsilateral axillary lymph node metastases. The diagnosis was microinvasive ductal cancer that was pT1miN1M0, pStage â
¡A, hormone receptor negative, and HER2 positive. Given the impact of this cancer on the prognosis of liver metastases of GIST, imatinib therapy, but not adjuvant chemotherapy, was started promptly for breast cancer after surgery. Four months after the surgery, left subclavian lymph node recurrence of breast cancer was found. Since the liver metastases of GIST had been stable, imatinib was discontinued, and paclitaxel and anti-HER2 therapy were administered. After confirming tolerability, imatinib was carefully added in combination. Because the lymph nodes shrank and liver metastases of GIST were stable, both anti-HER2 therapy and imatinib were continued. There are few reports of combined chemotherapy for synchronous double cancer, and we report our experience in which careful treatment was required.
Buscar en Google
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Tumores del Estroma Gastrointestinal
/
Neoplasias Hepáticas
Tipo de estudio:
Prognostic_studies
Límite:
Aged
/
Female
/
Humans
Idioma:
Ja
Revista:
Gan To Kagaku Ryoho
Año:
2021
Tipo del documento:
Article